

Hope on the Horizon for ADTKD Patients Webinar Recording Available

Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) is the second most common genetic kidney disease after Polycystic Kidney Disease, affecting an estimated 75,000–100,000 individuals in the United States and as many as two million people worldwide. While awareness of this rare condition has historically been limited, promising research is bringing new momentum—and hope—to the field.

C-Path recently hosted webinar, **“Hope on the Horizon for ADTKD Patients,” on April 9**. It was an opportunity to learn more about this underrecognized disease and the efforts underway to advance the first potential treatments targeting the **UMOD and MUC1** gene variants responsible for most ADTKD cases. With clinical trials expected in the near future, the landscape for patients and families affected by ADTKD may soon begin to change.

This session will highlighted the work of the Rare Kidney Disease Foundation, a patient-led organization dedicated to halting ADTKD across generations through education, advocacy, and community engagement. Featured speakers include:

- **Nadia N. Chaudhri**, MD, U.S. Food and Drug Administration
- **Sharon McGroder**, PhD, Rare Kidney Disease Foundation
- **Richard R. Nelson**, Rare Kidney Disease Foundation

Together, they shared insights on the patient journey, the growing understanding of ADTKD, and the collaborative efforts needed to accelerate research and therapeutic development.